Several questions were not addressed within the population studied in this phase 1 trial, such as responsiveness to single-agent anti-LAG-3 or the combination in treatment-naïve patients, and certain tumor types with high LAG-3 expression; the impact of high LAG-3 or PD-L1 expression also remains unclear (11, 21). This evidence concerns the gene STMN1 and neoplasm.